Free Trial
NASDAQ:CRGX

CARGO Therapeutics Q3 2024 Earnings Report

CARGO Therapeutics logo
$4.64 0.00 (0.00%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$4.64 +0.00 (+0.11%)
As of 04/17/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CARGO Therapeutics EPS Results

Actual EPS
-$0.88
Consensus EPS
-$1.14
Beat/Miss
Beat by +$0.26
One Year Ago EPS
N/A

CARGO Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CARGO Therapeutics Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

CARGO Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

CARGO Therapeutics Earnings Headlines

Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…
CARGO Therapeutics Stock (NASDAQ:CRGX) Jumps 20% on Buyout Hopes
See More CARGO Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CARGO Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CARGO Therapeutics and other key companies, straight to your email.

About CARGO Therapeutics

CARGO Therapeutics (NASDAQ:CRGX), a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

View CARGO Therapeutics Profile

More Earnings Resources from MarketBeat